| Catalog No. |
TD-HY057066 |
| Species reactivity |
Human |
| Applications |
Research Grade Biosimilar |
| Host species |
Humanized |
| Isotype |
scFv-TCR |
| Expression system |
Mammalian Cells |
| Species |
Human |
| Clonality |
Monoclonal |
| Target |
CD3E, gp100 peptide-HLA Complex, T3E, T-cell surface antigen T3/Leu-4 epsilon chain, CD3e, T-cell surface glycoprotein CD3 epsilon chain |
| Endotoxin level |
Please contact with the lab for this information. |
| Purity |
>95% as determined by SDS-PAGE. |
| Purification |
Purified by Nickel column. |
| Accession |
P07766 |
| Form |
Liquid |
| Storage buffer |
9mM Citric acid monohydrate, 41mM Na2HPO4, 1% Mannitol, 5% Trehalose, 0.02% Tween 20, 2mM DTT, pH 6.5. |
| Stability and Storage |
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term. |
| Alternate Names |
Bispecific fusion protein, CAS: 1874157-95-5 |
| Background |
Tebentafusp (IMCgp100) is a bispecific fusion protein to target gp100 peptide-HLA-A*02:01 (a melanoma-associated antigen). Tebentafusp guides T cells to kill gp100-expressing tumor cells via a high affinity T-cell receptor (TCR) binding domain and an anti-CD3 T-cell engaging domain. Tebentafusp leads to inflammatory cytokines and cytolytic proteins production, resulting in the direct lysis of tumour cells. |
| Note |
For research use only. Not suitable for clinical or therapeutic use. |